All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tisotumab Vedotin
Therapeutic Area: Oncology Product Name: GCT1015-04
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2021
Details:
The submission is based on the results of the innovaTV 204 pivotal phase 2 single-arm clinical trial evaluating tisotumab vedotin as monotherapy in this setting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: GEN3013
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $3,150.0 million Upfront Cash: $750.0 CHECK
Deal Type: Collaboration January 13, 2021
Details:
A USD 40 million milestone payment was triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator’s choice of chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Epcoritamab
Therapeutic Area: Oncology Product Name: GEN3013
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The study will evaluate the efficacy and safety of subcutaneous epcoritamab versus investigators’ choice of chemotherapy regimen (either bendamustine and rituximab or gemcitabine, oxaliplatin, and rituximab) in patients with relapsed or refractory DLBCL.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The allowance and imminent issuance of these three new DRP® biomarker patents further expands Allarity’s patent portfolio on unique, drug-specific DRP® biomarkers developed with its best-in-class and highly validated DRP® platform technology.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: TKI258
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2020
Details:
The Company is announcing an update on timing for its originally planned first NDA filing for dovitinib as a treatment for renal cell carcinoma (RCC). This NDA is based on non-inferiority to the approved drug sorafenib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2020
Details:
Phase 3 APOLLO randomized study evaluating subcutaneous daratumumab in combination with pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in relapsed or refractory multiple myeloma met the primary endpoint of improving progression-free survival.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dovitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Sass & Larsen ApS
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Details:
Oncology Venture has acquired the remaining 37% ownership in its priority Dovitinib program from investor Sass & Larsen ApS. As a result of the transaction, the Company now has full control of its most advanced pipeline program.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
